Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
triptan |
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02CC05
|
| gptkbp:brand |
Axert
|
| gptkbp:CASNumber |
154323-57-6
|
| gptkbp:chemicalClass |
sulfonamide
|
| gptkbp:contraindication |
stroke
ischemic heart disease uncontrolled hypertension |
| gptkbp:developedBy |
gptkb:Almirall
|
| gptkbp:eliminationHalfLife |
3-4 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C17H25N3O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
almotriptan
|
| gptkbp:interactsWith |
gptkb:MAO_inhibitors
gptkb:SSRIs gptkb:ergotamine |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
5-HT1B/1D receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:proteinBinding |
~70%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness drowsiness dry mouth |
| gptkbp:synonym |
almotriptan malate
|
| gptkbp:usedFor |
migraine
|
| gptkbp:bfsParent |
gptkb:triptans
|
| gptkbp:bfsLayer |
7
|